​

Syndax Pharmaceuticals (SNDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SNDX Stock Forecast

Syndax Pharmaceuticals (SNDX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $32.33, with a high of $44.00 and a low of $18.00. This represents a 107.91% increase from the last price of $15.55.

$10 $17 $24 $31 $38 $45 High: $44 Avg: $32.33 Low: $18 Last Closed Price: $15.55

SNDX Stock Rating

Syndax Pharmaceuticals stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (90.48%), 2 Hold (9.52%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 2 19 Strong Sell Sell Hold Buy Strong Buy

SNDX Price Target Upside V Benchmarks

TypeNameUpside
StockSyndax Pharmaceuticals107.91%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts135
Avg Price Target$44.00$32.33$30.40
Last Closing Price$15.55$15.55$15.55
Upside/Downside182.96%107.91%95.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25210---12
Aug, 252101--13
Jul, 25291--12
Jun, 25291--12
May, 25391--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2025Stifel Nicolaus$44.00$15.73179.72%182.96%
Jul 15, 2025David DaiUBS$35.00$9.80257.14%125.08%
Jul 10, 2025Corinne JohnsonGoldman Sachs$18.00$9.8283.30%15.76%
Nov 13, 2024George FarmerScotiabank$18.00$20.04-10.18%15.76%
Oct 24, 2024David DaiUBS$37.00$18.5499.57%137.94%
Aug 15, 2024Yigal NochomovitzCitigroup$34.00$20.0969.24%118.65%
Aug 15, 2024Jason ZemanskyBank of America Securities$31.00$19.5858.32%99.36%
Aug 15, 2024Peter LawsonBarclays$33.00$19.5868.54%112.22%
Jul 30, 2024Jason ZemanskyBank of America Securities$30.00$21.9936.43%92.93%
Jun 28, 2024Kelly ShiJefferies$37.00$20.3282.09%137.94%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 05, 2025CitigroupBuyBuyhold
Aug 05, 2025BTIGBuyBuyhold
Jul 15, 2025UBSBuyBuyhold
Jul 10, 2025Goldman SachsBuyBuyinitialise
May 06, 2025ScotiabankSector PerformSector Performhold
Nov 13, 2024ScotiabankSector PerformSector Performhold
Oct 24, 2024UBSBuyinitialise
Aug 15, 2024Cowen & Co.BuyBuyhold
Aug 15, 2024CitigroupBuyBuyhold
Aug 15, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.77$0.48$-2.37$-2.98$-3.73----
Avg Forecast$-1.86$-2.04$-2.53$-2.95$-3.48$-3.85$-2.65$-1.64$-0.32
High Forecast$-0.67$-0.73$-0.41$-2.88$-2.85$-3.24$-0.74$-0.96$-0.13
Low Forecast$-4.20$-4.60$-8.09$-3.13$-3.67$-4.50$-3.45$-2.43$-0.74
Surprise %-4.84%-123.53%-6.32%1.02%7.18%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.52M$139.71M--$23.68M----
Avg Forecast$1.47M$19.15M$375.00K-$48.72M$98.48M$234.54M$347.18M$537.00M
High Forecast$2.88M$37.59M$1.01M-$134.94M$132.74M$234.55M$688.50M$1.06B
Low Forecast$740.87K$9.68M$132.85K-$23.22M$59.51M$234.52M$184.39M$285.21M
Surprise %3.54%629.55%---51.40%----

Net Income Forecast

$-600M $-470M $-340M $-210M $-80M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-73.07M$24.93M$-143.75M$-209.36M$-318.76M----
Avg Forecast$-131.15M$-143.68M$-178.14M$-209.36M$-229.54M$-272.53M$-240.79M$-124.49M$-22.82M
High Forecast$-46.87M$-51.34M$-28.60M$-202.38M$-200.80M$-228.32M$-52.08M$-67.65M$-8.91M
Low Forecast$-295.33M$-323.55M$-569.42M$-220.52M$-258.27M$-316.74M$-242.60M$-171.23M$-51.99M
Surprise %-44.28%-117.35%-19.31%-38.87%----

SNDX Forecast FAQ

Is Syndax Pharmaceuticals stock a buy?

Syndax Pharmaceuticals stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Syndax Pharmaceuticals is a favorable investment for most analysts.

What is Syndax Pharmaceuticals's price target?

Syndax Pharmaceuticals's price target, set by 21 Wall Street analysts, averages $32.33 over the next 12 months. The price target range spans from $18 at the low end to $44 at the high end, suggesting a potential 107.91% change from the previous closing price of $15.55.

How does Syndax Pharmaceuticals stock forecast compare to its benchmarks?

Syndax Pharmaceuticals's stock forecast shows a 107.91% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Syndax Pharmaceuticals over the past three months?

  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 15.38% Strong Buy, 76.92% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Syndax Pharmaceuticals’s EPS forecast?

Syndax Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.85, marking a 3.22% increase from the reported $-3.73 in 2024. Estimates for the following years are $-2.65 in 2026, $-1.64 in 2027, and $-0.32 in 2028.

What is Syndax Pharmaceuticals’s revenue forecast?

Syndax Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $98.48M, reflecting a 315.88% increase from the reported $23.68M in 2024. The forecast for 2026 is $234.54M, followed by $347.18M for 2027, and $537M for 2028.

What is Syndax Pharmaceuticals’s net income forecast?

Syndax Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-273M, representing a -14.50% decrease from the reported $-319M in 2024. Projections indicate $-241M in 2026, $-124M in 2027, and $-22.823M in 2028.